



# NLR Multi-annual Strategy 2024-2028

Together we end leprosy!



Name | Location

**29 juli 2024**

---



# We are NLR

---

Leprastichting/  
international office  
**Netherlands**

NLR  
**Nepal**

NLR  
**India**

NLR  
**Indonesia**

NHR  
**Brasil**

NLR  
**Moçambique**



# We are NLR

**220**  
staff

An  
**alliance**  
of 6 NGO's

**€12**  
million  
budget

**55**  
years  
experience

Leprastichting/  
international office  
**Netherlands**

NLR  
**Nepal**

**India**

NLR  
**Indonesia**

NHR  
**Brasil**

NLR  
**Moçambique**



# Where we Work

---

Leprastichting/  
international office  
**Netherlands**

NLR  
**Nepal**

NLR  
**India**

NLR  
**Indonesia**


NHR  
**Brasil**

NLR  
**Moçambique**



## Leprosy: facts, figures and myths

---





# Working together to fight leprosy





## We started with a dream

Since 1967, NLR has strived to make leprosy a disease of the past.

Ciska Anten and Dr. Leiker founded Leprastichting (NLR).



## Much has been achieved

In the 1960s, around three million leprosy patients worldwide were facing lifelong treatment.

Now, around 200,000 new leprosy patients are detected each year around the globe.



## Vision and mission

**Our vision:** a world free of leprosy and its consequences.

**Our mission:** to prevent, detect, and treat leprosy, and to support the health, ability, and full inclusion in society for persons affected by leprosy.




## Zero leprosy\* by 2040

NLR's overall goal is zero leprosy by 2040. After 4,000 years, *we are the generation* that can end one of the world's oldest and most notorious diseases with the right knowledge, support and collaboration

*\* Zero leprosy = no new patients*



## Where are we today



NLR NGOs work in India, Indonesia, Brazil, Mozambique, and Nepal, where 85% of leprosy patients live. Support from international office in the Netherlands with knowledge and funding.

### **NLR's developments**

- From supporting governments in detection and treatment of leprosy patients >>>
- Research into the feasibility of preventive treatment >>>
- Innovating new interventions and advocating for scale up of effective prevention tools




## Where are we today

### Prevention and modelling

Models developed together with Erasmus Medical Centre (Netherlands) show that to reduce the incidence of leprosy by 90% over the next 22 years, the cumulative number of individuals requiring preventive treatment\* is projected at 40 million.

*\*Embraced by WHO, but not yet implemented by health systems at maximum speed.*

### People requiring PEP






# Combining our Strengths with Stakeholder Needs

## Our strengths

- 55 years track record in evidence-based programmes
- Strong reputation and leading partner in many national and international networks and partnerships
- Technical leprosy expertise combined with programmatic know-how
- Development and implementation of innovative approaches (PEP, PEP++).
- Stable funding from **46,500** loyal donors in the Netherlands and international institutional funders





## Strategic direction

- Follow WHO leprosy strategy and work together with their teams towards clear elimination goal – the 'endgame'
- Strengthen and support government National Leprosy Programmes to implement country owned roadmaps
- Focus on and scale up of innovations for leprosy prevention: SDR-PEP, PEP++
- By 2028, we aim to contribute to a 50% decrease of annual new leprosy patients detected in the following countries (compared to 2021):

Country	2019	2021	2028
<b>Brazil</b>	27.863	18.318	9.159
<b>India</b>	114.451	75.394	37.697
<b>Indonesia</b>	17.439	10.976	5.488
<b>Moçambique</b>	2.220	3.135	1.568
<b>Nepal</b>	3.844	2.394	1.197
<b>Totals</b>	165.817	110.217	55.109



# How NLR Contributes to a World Without Leprosy: Five strategic goals

## Zero leprosy by 2040

50% decrease of annual new leprosy patients detected in NLR countries

### Impact Goals

1. National governments accelerate the elimination of leprosy

2. Prevention of leprosy is scaled up supported by PEP services

3. Persons affected by leprosy enjoy equal rights and opportunities



Research & Innovation



Advocacy & Technical Support



Learning and Development

### Strategic foundation

4. A solid funding base, relevant visibility and strong reputation

5. A strong alliance through national leadership and international support

**NLR: Brazil, India, Indonesia, Mozambique, Nepal and the Netherlands**



# 1. National governments accelerate the elimination of leprosy. They have implementation plans that include adequate funding.



## PEP-services



NLR will make sure leprosy prevention and the implementation of PEP-services is an important element in national strategies.



## Advocacy



NLR plays a key role in advocating for national governments to make commitments to leprosy control and elimination.



## Expert input



In countries outside the alliance, NLR will support process towards verification of elimination of leprosy with expert input.



## 2. Prevention of leprosy is scaled up significantly, invigorating leprosy control programmes supported by PEP services.



### SDR-PEP



Leprosy is now preventable with a **single dose** of the **antibiotic** rifampicin (SDR-PEP) given to close contacts of a leprosy patient.

SDR-PEP **reduces the risk of developing leprosy by 60%** and it is cost-effective.



### PEP++



The 'Stop the transmission of leprosy!' project seeks to confirm that a **three-dose regimen of two antibiotics** (rifampicin and clarithromycin) will be **effective for 80-90%**.



### GIS mapping



Identify "hotspots" with GIS-mapping (**geographic information system**).

This technology helps to target interventions and determine the best SDR-PEP implementation strategy.



### LEMT



The WHO strategy is working towards elimination of leprosy (defined as interruption of transmission).

The **Leprosy Elimination Monitoring Tool** has been developed to monitor this.

### 3. Persons affected by leprosy enjoy equal rights and opportunities.



#### Participation



Participate equally  
in development and  
decision-making processes  
in society



#### Equitable access



Have equitable access to all  
essential services




#### Equal opportunity




Have equal opportunity to  
achieve mental well-being




## 4. A solid funding base, relevant visibility, and strong reputation enable us to achieve leprosy goals.




### Income




We will diversify sources and increase the income of the NLR alliance globally and nationally




### Fundraising



Fundraising and communication approaches are based on donor needs and matching mutual objectives.



### Partnerships



NLR will build new, long-term partnerships with (potential) funders, donors, and consortium partners.



## 5. A strong NLR alliance enables us to achieve leprosy goals through national leadership and international support.



### Shifting leadership



Shifting leadership towards leprosy-endemic countries.



### Knowledge development



Attracting, retaining, and developing the staff and skills needed to achieve the goals in this multi-annual strategy.



### Capacity strengthening



We will elaborate on our strategic advocacy role.



## NLR's Five Strategic Goals

---

1. National governments accelerate the elimination of leprosy.
2. Prevention of leprosy is scaled up significantly. NLR supports programmes with PEP services.
3. Persons affected by leprosy enjoy equal rights and opportunities.
4. A solid funding base, relevant visibility, and strong reputation.
5. A strong NLR alliance through national leadership and international support.



## Monitoring & reviewing the strategy

---



**Review and planning  
workshops**



**NLR Annual Reports  
show progress**



**Adapt our decisions  
and approaches to  
changes we encounter**



## In conclusion: beginning of the end game

---

- WHO has identified leprosy as one of three neglected tropical diseases that can be eliminated in the near future.
- In eight years, 120 countries are estimated to report no new leprosy patients.
- NLR wishes to contribute to a 50% decrease in annual new leprosy patients in NLR alliance countries (compared to 2021).
- Achieving our ambitious goals depends on strong collaboration with WHO, governments, donors, partners and colleagues.
- NLR has developed a new and very effective tool: one dose of the antibiotic rifampicin. By scaling up this innovation, we can break the chain of infection and prevent leprosy, disabilities, stigma and social exclusion.





**Help us achieve our dream:  
a world without leprosy in 2040.**

---



until  
**No Leprosy Remains**

---